About Galapagos NV - American Depositary Shares (GLPG)
Galapagos NV is a biotechnology company focused on the discovery and development of innovative treatments for a variety of diseases, particularly those affecting the immune system and the central nervous system. The company leverages its proprietary target discovery platform and extensive drug development expertise to create therapeutics that aim to address significant unmet medical needs. With a commitment to advancing science through collaboration and research, Galapagos-NV works towards bringing novel therapies from laboratory to clinic, ultimately striving to improve patient outcomes and quality of life. Read More
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.
Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T therapies under CEO Paul Stoffels.
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
